509 related articles for article (PubMed ID: 36361831)
21. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
22. Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.
Harper J; Burke S; Travers J; Rath N; Leinster A; Navarro C; Franks R; Leyland R; Mulgrew K; McGlinchey K; Brown L; Dovedi SJ; Koopmann JO; Durham NM; Cheng X; Jin H; Eyles J; Wilkinson RW; Carroll D
Mol Cancer Ther; 2021 Sep; 20(9):1723-1734. PubMed ID: 34224361
[TBL] [Abstract][Full Text] [Related]
23. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
24. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
[TBL] [Abstract][Full Text] [Related]
25. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma.
Cuoco JA; Rogers CM; Mittal S
Neurosurg Focus; 2021 Feb; 50(2):E8. PubMed ID: 33524945
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer.
Zhang Y; Li Y; Chen K; Qian L; Wang P
J Cancer Res Ther; 2022 Sep; 18(5):1247-1255. PubMed ID: 36204869
[TBL] [Abstract][Full Text] [Related]
27. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.
Wang G; Kang X; Chen KS; Jehng T; Jones L; Chen J; Huang XF; Chen SY
Nat Commun; 2020 Mar; 11(1):1395. PubMed ID: 32170083
[TBL] [Abstract][Full Text] [Related]
28. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
29. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.
Ghonime MG; Saini U; Kelly MC; Roth JC; Wang PY; Chen CY; Miller K; Hernandez-Aguirre I; Kim Y; Mo X; Stanek JR; Cripe T; Mardis E; Cassady KA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599026
[TBL] [Abstract][Full Text] [Related]
30. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.
Vigil A; Martinez O; Chua MA; García-Sastre A
Mol Ther; 2008 Nov; 16(11):1883-90. PubMed ID: 18714310
[TBL] [Abstract][Full Text] [Related]
31. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
32. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
Meng Q; He J; Zhong L; Zhao Y
Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
[TBL] [Abstract][Full Text] [Related]
33. A Dual-Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis.
Su W; Qiu W; Li SJ; Wang S; Xie J; Yang QC; Xu J; Zhang J; Xu Z; Sun ZJ
Adv Mater; 2023 Mar; 35(11):e2209379. PubMed ID: 36545949
[TBL] [Abstract][Full Text] [Related]
34. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
35. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
[TBL] [Abstract][Full Text] [Related]
36. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
38. Safety and clinical usage of newcastle disease virus in cancer therapy.
Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB
J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816
[TBL] [Abstract][Full Text] [Related]
39. Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses.
Vannini A; Leoni V; Campadelli-Fiume G
Adv Exp Med Biol; 2021; 1290():67-80. PubMed ID: 33559855
[TBL] [Abstract][Full Text] [Related]
40. Single-cell transcriptomics of peripheral blood reveals anti-tumor systemic immunity induced by oncolytic virotherapy.
Wu Q; Hu X; Zhang X; Kong D; Yang Z; Li G; Gu Z; Zhang Q; Wan D; Cheng S; Liu B; Zhang K; Zhang W
Theranostics; 2022; 12(17):7371-7389. PubMed ID: 36438484
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
